Practical, structured writing on Chinese MedTech international growth

Market Insights

AI in MedTech: Why the Payer Question Matters More Than the Algorithm

AI has transformed consumer applications at speed, but in healthcare the pace is deliberately slower—and for good reason. The barriers are structural: clinical evidence requirements, multi-stakeholder decision chains, regulatory approval in every target market, and fragmented reimbursement systems that vary dramatically by country. Understanding these dynamics explains why IBM Watson failed, why many well-funded AI health companies still lack a scalable revenue model, and what Chinese MedTech companies must think through before committing to an AI-led international expansion.

Insight·21 Jun 2026·7 min read

Market Insights

Choosing Markets, Not Chasing Opportunities: The First Strategic Decision in MedTech Internationalization

After years of working with Chinese MedTech companies on international expansion, a pattern emerges consistently: companies spend three to four years and significant resources in a market, only to discover that its total addressable size was always limited, or that competitors had already locked in the key channels long before entry. This is not a sales execution problem—it is the consequence of a decision that was never made rigorously in the first place. Systematic target market selection is the foundation of any credible international strategy, and the single decision most likely to determine whether overseas investment compounds or simply accumulates as sunk cost.

Insight·20 Jun 2026·6 min read

Channel Development

After You Cut the Price, What’s Left? Pricing Strategy for Chinese MedTech Going Global

Low pricing is the most accessible tool for Chinese MedTech companies entering international markets — and often the most damaging one to overuse. This article examines the structural costs of price-led market entry: why lower prices can actually reduce sales velocity in certain segments, what genuinely successful international MedTech companies are really selling, and what pricing decisions reveal about a company's long-term strategic intent.

Insight·20 Jun 2026·5 min read

Global Expansion Strategy

Regulatory Clearance Is Not a Market Entry Strategy

Regulatory registration is the unavoidable first gate for Chinese MedTech companies entering international markets. But obtaining a registration certificate does not mean opening a market. Across numerous client engagements, a consistent pattern emerges: companies treat registration as a goal rather than an investment, neglect upstream strategic decisions about market prioritization and certificate ownership, and end up with approvals that generate little commercial return. This article examines how to reframe overseas registration as an investment decision — and how to balance internal capability development with external execution.

Insight·20 Jun 2026·5 min read